Provider Briefing: Tivicay Availability in 2026

If your patients have reported difficulty filling their Tivicay (Dolutegravir) prescriptions, this briefing covers what's changed, what's driving the access issues, and what you can do to support continuity of care.

While Tivicay is not in a formal shortage, several market and distribution factors have created real barriers for patients trying to fill prescriptions at retail pharmacies.

Timeline of Key Changes

Understanding the recent history helps contextualize today's access challenges:

• August 2013: FDA approves Tivicay (Dolutegravir) 50 mg tablets for HIV-1 treatment
• 2014–2023: Tivicay becomes a cornerstone of INSTI-based regimens; combination products Triumeq (2014), Juluca (2017), and Dovato (2019) launched
• December 2023: ViiV Healthcare announces discontinuation of 10 mg and 25 mg tablet strengths
• January 2024: 10 mg and 25 mg tablets officially discontinued; only 50 mg tablets and Tivicay PD 5 mg dispersible tablets remain
• 2024–2026: Increased use of combination products (Dovato, Biktarvy) reduces standalone Tivicay demand at retail pharmacies, narrowing distribution

Prescribing Implications

The discontinuation of lower-strength tablets has several clinical implications:

Dose Adjustments

Patients previously titrated on 10 mg or 25 mg tablets will need regimen reassessment. For adult patients, the standard dose remains 50 mg once daily (or 50 mg twice daily with certain inducers or in INSTI-experienced patients with resistance).

Pediatric Considerations

Tivicay PD (5 mg dispersible tablets) remains available for patients weighing 3 kg to less than 20 kg. For children weighing 20 kg or more, the 50 mg film-coated tablet is used with weight-based dosing. The loss of intermediate strengths may complicate dosing for some pediatric patients in transition.

Drug Interactions Requiring Dose Modification

Remember that 50 mg twice daily dosing is required when co-administered with:

• Rifampin
• Efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir
• Carbamazepine, oxcarbazepine, phenytoin, phenobarbital

Dofetilide remains contraindicated due to OCT2-mediated interaction risk.

Current Availability Picture

Tivicay 50 mg is not on the FDA or ASHP drug shortage lists as of early 2026. However, practical availability is affected by:

• Specialty distribution: Many retail pharmacies do not routinely stock Tivicay. HIV medications are increasingly channeled through specialty and mail-order pharmacies.
• Single-source supply: No generic Dolutegravir is available in the U.S. (patent expiration: June 2030). ViiV Healthcare is the sole manufacturer.
• Formulary positioning: Payers have increasingly favored combination products (Dovato, Biktarvy, Triumeq) over standalone Tivicay, reducing stocking at many pharmacies.

Cost and Access Considerations

The cash price for Tivicay 50 mg (30 tablets) ranges from $2,800 to $2,925. Key financial support pathways include:

• ViiVConnect Savings Card: For commercially insured patients; may reduce copay to $0. Enroll at myviivcard.com.
• ViiV Patient Assistance Program: For uninsured/underinsured patients meeting income criteria. Information at viivconnect.com.
• AIDS Drug Assistance Programs (ADAP): State-run programs covering HIV medications for low-income patients.
• Ryan White HIV/AIDS Program: Federal funding for HIV care including medication coverage.
• 340B pricing: Eligible covered entities can obtain Tivicay at significantly reduced cost.

For a patient-facing cost guide you can share, see: How to Save Money on Tivicay.

Tools and Resources for Your Practice

Several resources can help streamline Tivicay access for your patients:

• Medfinder for Providers: medfinder.com/providers — Check real-time pharmacy availability and help patients locate Tivicay in stock
• ViiVConnect HCP Portal: Access prescribing pathways, reimbursement support, and patient financial assistance enrollment
• Specialty Pharmacy Networks: Partner with HIV-focused specialty pharmacies that reliably stock Tivicay and other antiretrovirals

Looking Ahead

The HIV treatment landscape continues to shift toward combination products and long-acting injectables. While standalone Tivicay remains an important option — particularly for patients with complex regimens or specific resistance profiles — providers should anticipate continued narrowing of retail distribution.

Key developments to watch:

• Generic Dolutegravir entry expected after June 2030
• Continued expansion of long-acting injectable options (Cabenuva, lenacapavir)
• Potential formulary changes as payers respond to pipeline developments

Final Thoughts

Tivicay remains a highly effective INSTI with strong clinical data. The access challenges your patients face are primarily distribution- and market-driven, not supply-driven. By leveraging specialty pharmacy networks, manufacturer support programs, and tools like Medfinder, you can help ensure your patients maintain uninterrupted access to their HIV treatment.

For a practical guide on helping patients find Tivicay, see: How to Help Your Patients Find Tivicay in Stock.